Details of the Drug

General Information of Drug (ID: DMWE2N4)

• Drug Name: Auranofin
• Synonyms: Ridaura; Ridauran; Ridaura (TN); SK&F 39162; SK&F-39162; Gold, (1-thio-.beta.-D-glucopyranosato)(triethylphosphine)-, 2,3,4,6-tetraacetate; (1-Thio-.beta.-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate

Indication

Disease Entry	ICD 11	Status	REF
Inflammatory arthritis	FA2Z	Approved	[1]

• Therapeutic Class: Antirheumatic Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 2:
  Molecular Weight; 678.5
  Logarithm of the Partition Coefficient; Not Available
  Rotatable Bond Count; 12
  Hydrogen Bond Donor Count; 0
  Hydrogen Bond Acceptor Count; 10
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 4: low solubility and low permeability [2]
  Elimination: 60% of drug is excreted from urine in the unchanged form [2]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Diarrhoea (excl infective)	Not Available	MT1A	OTKBH52X	[3]

• Chemical Identifiers:
  Formula: C20H34AuO9PS
  IUPAC Name: gold(1+);3,4,5-triacetyloxy-6-(acetyloxymethyl)oxane-2-thiolate;triethylphosphane
  Canonical SMILES: CCP(CC)CC.CC(=O)OCC1C(C(C(C(O1)[S-])OC(=O)C)OC(=O)C)OC(=O)C.[Au+]
  InChI: InChI=1S/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/q;;+1/p-1
  InChIKey: AUJRCFUBUPVWSZ-UHFFFAOYSA-M
• Cross-matching ID:
  PubChem CID: 24199313
  CAS Number: 34031-32-8
  DrugBank ID: DB00995
  TTD ID: D0L2UN
  VARIDT ID: DR01329
  ACDINA ID: D00051
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Steroid hormone receptor ERR (ESRR)	TTP3UTW	ERR1_HUMAN ; ERR2_HUMAN ; ERR3_HUMAN	Modulator	[4]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[5]
Multidrug and toxin extrusion protein 1 (SLC47A1)	DTZGT0P	S47A1_HUMAN	Substrate	[5]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Metallothionein-1A (MT1A)	OTKBH52X	MT1A_HUMAN	Drug Response	[3]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Auranofin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of peripheral neuropathy by the combination of Auranofin and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[6]
Thalidomide	DM70BU5	Moderate	Increased risk of peripheral neuropathy by the combination of Auranofin and Thalidomide.	Multiple myeloma [2A83]	[7]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Auranofin and Ocrelizumab.	Multiple sclerosis [8A40]	[8]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive myelosuppressive effects by the combination of Auranofin and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[9]
Ganciclovir	DM1MBYQ	Moderate	Increased risk of nephrotoxicity by the combination of Auranofin and Ganciclovir.	Virus infection [1A24-1D9Z]	[10]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Auranofin and Valganciclovir.	Virus infection [1A24-1D9Z]	[10]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Benzyl alcohol	E00010	244	Antimicrobial preservative; Solvent
Cetylpyridinium chloride	E00330	31239	Antimicrobial preservative; Penetration agent; Solubilizing agent; Surfactant
D&C red no. 33	E00261	19116	Colorant
FD&C blue no. 1	E00263	19700	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Auranofin 3 mg capsule	3 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6306).
• [2] BDDCS applied to over 900 drugs
• [3] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Selection and characterization of a human ovarian cancer cell line resistant to auranofin. Oncotarget. 2017 Oct 9;8(56):96062-96078.
• [6] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
• [7] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
• [8] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [9] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [10] Cerner Multum, Inc. "Australian Product Information.".